To evaluate the effect of supplementation of dialysis fluid with N-acetylglucosamine (NAG) on the permeability of peritoneum during chronic peritoneal dialysis in rats.
Design
Experiments were performed on rats with surgically implanted peritoneal catheters. Dialysis solution [DianeaI1.5% (Baxter, Deerfield, IL, U.S.A.) supplemented with either NAG 50 mmol/L or glucose 50 mmol/L (control)] was infused intraperitoneally twice, every day, for 8 weeks. Peritoneal equilibration tests (PET) were performed in all animals at the beginning of the study and after 8 weeks of dialysis. Additionally, at the end of each week, dialysis solution infused in the morning was drained after 4 hours of intraperitoneal dwell. White blood cell count, creatinine, and total protein concentrations were measured in the effluent dialysate. After 8 weeks of dialysis, the morphology of the peritoneum was studied.
Results
In rats exposed to dialysis fluid supplemented with NAG, peritoneal permeability to creatinine and proteins was reduced when compared to animals dialyzed with glucose solution. In NAG treated animals, staining with alcian blue for polyanions in the peritoneal interstitium was significantly stronger than in rats dialyzed with glucose solution.
Conclusions
Chronic peritoneal dialysis with dialysis solution supplemented with N-acetylglucosamine causes accumulation of glycosaminoglycans in the peritoneal interstitium, which results in a change of peritoneal permeability.
HolmesC.J.Biocompatibility of peritoneal dialysis solutions.Perit Dial Int1993; 13: 88–94.
3.
Di PaoloN., SacchiG., De MiaM.Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis.Nephron1986; 44: 204–11.
4.
HeimbürgerO., WaniewskiJ., WerynskiA., TranaeusA., LindholmB.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int1990; 38: 495–506.
5.
ColesG.A.Biocompatibility of various osmotic solutes.Perit Dial Int1995; 15(7): S71–5.
6.
MistryC.D., GokalR.Optimal use of glucose polymer (icodextrin) in peritoneal dialysis.Perit Dial Int1996; 16(Suppl 1): S104–8.
7.
TopleyN., KaurD., PetersenM.M., JörresA., Passlick DeetjenJ., ColesG.A.Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function.Kidney Int1996; 49: 1447–56.
8.
WieslanderA.P., NordinM.K., MartinsonE., KjellstrandP.T.T., BobergU.C.Heat sterilized PD fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes.Clin Nephrol1993; 39: 343–8.
9.
BosH.J., StruijkD.G., TukC.W., De VeldJ.C., HelehorstT.J.M., HoefsmitE.C.M.Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence.Nephron1991; 59: 508–9.
10.
LibettaC., De NicolaL., RampinoT., De SimoneW., MemoliB.Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation.Kidney Int1996; 49: 506–11.
11.
GotloibL., ShostackA., Bar SellaP., CohenR.continuous mesothelial injury and regeneration during long term peritoneal dialysis.Perit Dial Bull1987; 7: 148–55.
12.
YungS., ColeG.A., WilliamsJ.D., DaviesM.The source and possible significance of hyaluronan in the peritoneal cavity.Kidney Int1994; 46: 527–33.
13.
WieczorowskaK., BreborowiczA., MartisL., OreopoulosD.G.Protective effect of hyaluronic acid against peritoneal injury.Perit Dial Int1995; 15: 81–3.
14.
BreborowiczA., Wieczorowska-TobisK., KuzlanM., KupszJ., KorybalskaK., PolubinskaA.N-Acetylglucosamine: A new osmotic solute in peritoneal dialysis solutions.Perit Dial Int1997; 17(Suppl 2): S80–3.
15.
LowryO.H., RosenbroughN.J., RarrA.L.Protein measurement with the folin phenol reagent.J Biol Chem1951; 193: 265–75.
16.
ComperW.D., LaurentT.C.Physiological function of connective tissue polysaccharides.Physiol Rev1978; 58: 255–319.
17.
WeigelP.H., FullerG.M., LeBoeufR.D.A model for the role of hyaluronic acid and fibrin in early events during the inflammatory response and wound healing.J Theor Biol1986; 119: 219–26.
18.
BreborowiczA., WieczorowskaK., MartisL., OreopoulosD.G.Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats.Nephron1994; 67: 346–50.
19.
BazzatoG., FracassoA., GambaroG., BaggioB.Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis.Lancet1995; 346: 740–1.
20.
RodenL.Effect of hexosamines on the synthesis of chondroitin sulphuric acid in vitro.Arkiv for Kemi1956; 10: 345–52.
21.
HueyG., MoiinA., SternR.Levels of [3H]glucosamine incorporation into hyaluronic acid by fibroblasts is modulated by culture conditions.Matrix1990; 10: 75–83.
22.
WhitemanP.The quantitative measurement of alcianblue glycosaminoglycan complexes.Biochem J1973; 131: 343–50.
23.
OgstonA.G., ShermanT.F.Effects of hyaluronic acid upon diffusion of solutes and flow of solvent.J Physiol1961; 156: 67–74.
24.
BreborowiczA., RadkowskiM., KnapowskiJ., OreopoulosD.G.Effects of chondroitin sulphate on fluid and solute transport during peritoneal dialysis in rats.Perit Dial Int1991; 11: 351–4.
25.
GambaroG., CavazzanaA.O., LuziP., PiccoliA., BorsatiA., CrepaldiG.Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats.Kidney Int1992; 42: 285–91.
26.
RaoN.V., KennedyT.P., RaoG., KyN., HoidalJ.R.Sulfated polysaccharides prevent human leukocyte elastaseinduced acute lung injury and emphysema in hamsters.Am Rev Respir Dis1990; 142: 407–12.
27.
AkatsukaM., YamamotoY., TobettoK., YasuiT., AndoT.Suppressive effects of hyaluronic acid on elastase release from rat peritoneal leukocytes.J Pharm Pharmacol1993; 45: 110–14.
28.
FibbiG., VannucchiS., CavalliniP., Del RossoM., PasqualiF., CappellettiR.Involvement of chondroitin sulphate in preventing adhesive cellular interactions.Biochim Biophys Acta1983; 762: 512–18.
KingS.R., HickersonW.L., ProctorK.G.Beneficial actions of exogenous hyaluronic acid on wound healing.Surgery1991; 109: 76–84.
31.
GriesE., PaarD., GrabenN., BockK.D.Intraperitoneal fibrin- formation and its inhibition in CAPD.Clin Nephrol1986; 26: 209–12.
32.
DobbieJ.W.Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.Perit Dial Int1992; 12: 14–27.
33.
HakanssonL., VengeP.The molecular basis of the hyaluronic acid-mediated stimulation of granulocyte function.J Immunol1987; 138: 4347–52.
34.
GerdinB., HallgrenR.Dynamic role of hyaluronan (HYA) in connective tissue activation and inflammation.J Intern Med1997; 242: 49–55.
35.
ZakariaE.R., LofthouseJ., FlessnerM.F.Fluid loss from the peritoneal cavity is dependent on dilution and washout of the interstitial matrix (Abstract).J Am Soc Nephrol1997; 8: 294A.
36.
KohnP., WinzlerR.J., HoffmannR.C.Metabolism of D-glucosamine and N-acetyl-D-glucosamine in the intact rat.J Biol Chem1962; 237: 304–8.
37.
LaurentU.B.G., ReedR.K.Turnover of hyaluronan in the tissues.Adv Drug Del Rev1991; 7: 237–56.
